Kinesio Taping in Stroke Patient (Kinesio taping)

December 18, 2023 updated by: Taiwan Municipal An-Nan Hospital-China Medical University

Improved Hand Function in High-functioning Stroke Survivors by Applying Kinesio Taping: A Prospective Clinical Trial

Despite being nearly independent in daily life, chronic high-functioning stroke survivors still experienced mild impairments in skilled hand function. Kinesio Taping (KT) has been used to help stroke patients improve their balance and ambulation. Few studies explored the effects of KT on fine motor function in stroke patients. The purpose of this study was to investigate the hand function performance of high-functioning stroke survivors after KT. Participants were divided into two groups: KT group and control group. Last two days, the KT group received KT intervention. After the taping was removed, baseline and post-test evaluation were conducted. Outcome measures included muscle strength, range of motion (ROM), spasticity, fine motor function, and self-reported upper limb disability. The results revealed that the KT group had less spasticity, increasing ROM trend, and improved fine motor function and disability. KT improved spasticity, active movement, and muscle flexibility, resulting in more skilled and delicate hand function in chronic high-functioning stroke survivors.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
17

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Tainan, Taiwan, 709
        • An Nan Hospital, China Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • (1) Stroke with unilateral hemiparesis, (2) onset duration > 6 months, (3) Brunnstrom stage in the proximal and distal parts of the upper extremity > stage III, and (4) adequate cognitive ability to understand and cooperate with the experiment procedure.

Exclusion Criteria:

  • Participants with skin problem (such as allergies, open wound), a history of upper extremity musculoskeletal diseases (such as fractures, tendon ruptures), or other peripheral neurological or systemic diseases were excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: KT group
Participants in the KT group were applied I-shaped Kinesio tape to the wrist extensor and pronator teres of the hemiplegic forearm for 2 days. Throughout the 2-day experiment, all participants received regular conventional rehabilitation.
Other: Kinesio taping
Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
No Intervention: CT group
Participants in the CT group did not receive tape intervention but received regular conventional therapy.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Muscle strength
Time Frame: Baseline and post-test( 2 days later)
The maximum grip force and the muscle strength of the wrist extensor and flexor
Baseline and post-test( 2 days later)
AROM and PROM
Time Frame: Baseline and post-test( 2 days later)
The AROM and PROM of wrist flexion and extension (AROM and PROM in degrees). The AROM and PROM of the wrist flexion and extension were measured with the goniometers.
Baseline and post-test( 2 days later)
Spasticity
Time Frame: Baseline and post-test( 2 days later)
Spasticity of wrist and finger flexor and extensor. The spasticity of wrist and finger flexor and extensor were assessed with modified Ashworth Scale (MAS).
Baseline and post-test( 2 days later)
The Action Research Arm Test
Time Frame: Baseline and post-test( 2 days later)
gross motor and fine motor function of the upper limb, which included grasp, grip, pinch, and gross movement
Baseline and post-test( 2 days later)
Quick DASH
Time Frame: Baseline and post-test( 2 days later))
To measure the disability and symptoms of the upper limb, participants self-reported the Disability of the Arm, Shoulder and Hand (Quick DASH) questionnaire
Baseline and post-test( 2 days later))

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Taiwan Municipal An-Nan Hospital-China Medical University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Ya-Wen Tsai, MS, Department of Rehabilitation, An Nan Hospital, China Medical University, Tainan, Taiwan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 4, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 9, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 9, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 12, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 18, 2023

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 3, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 3, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 18, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TMANH108-REC009 (Other Identifier: institutional review board of Taiwan Municipal An Nan Hospital-China Medical University)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings